NADPH Oxidase–Mediated ROS in Pulmonary Arterial Hypertension
A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Antioxidant Enzyme Systems".
Deadline for manuscript submissions: closed (31 January 2019) | Viewed by 9224
Special Issue Editor
Interests: reactive oxygen species (ROS); NADPH oxidase; Galectin-3; PAH; vascular remodeling; redox signaling; adventitia; inflammation; vascular biology
Special Issue Information
Dear Colleagues,
Pulmonary arterial hypertension (PAH) is a progressive disease that involves the loss of endothelial function together with aberrant smooth muscle cell growth, inflammation, and fibrosis that involves multiple cell types in the pulmonary arteries (PA). How PAH develops remains incompletely understood, but evidence for production of reactive oxygen species (ROS) in PA has been well documented. There are many different types of ROS with multiple sources that may contribute to the pulmonary arterial remodeling that is a hallmark of PAH. The NADPH oxidase (Nox) family is comprised of seven structurally related transmembrane NADPH-dependent oxidoreductases that include the Nox enzymes, as well as the Duoxes. Accumulating evidence strongly suggests that ROS derived from NADPH oxidase play an important role in pulmonary arterial remodeling. The signaling mechanisms leading to activation of the Nox enzymes are diverse, and more precise targeting of the major sources of ROS in specific cell types in PA will likely be more effective towards development of therapeutic treatments for PAH.
The goal of this Special Issue is to bring together and outline the current state and importance of the role of NADPH oxidases in the context of PAH. Suppressing pathophysiological levels of ROS by manipulating NOX enzymes, their regulators, and effector ROS targets appears to be attractive therapeutic strategies to treat PAH and other related pulmonary vascular diseases. This Special Issue invites original research and review articles on the subject of NADPH-oxidases in the context of pulmonary vascular pathophysiology and all the related topics indicated below:
Prof. Scott A. Barman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Reactive Oxygen Species
- Inflammation
- Pulmonary Arterial Hypertension
- Redox Signaling
- Endothelial Cell
- Pulmonary Arterial Remodeling
- Adventitia
- Fibrosis
